Enantioselective inhibition of the formalin paw late phase by the NK1 receptor antagonist L-733,060 in gerbils

[1]  S. Boyce,et al.  Antinociceptive activity of the tachykinin NK1 receptor antagonist, CP‐99,994, in conscious gerbils , 1995, British journal of pharmacology.

[2]  R. Hargreaves,et al.  Comparison of the effects of sumatriptan and the NK1 antagonist CP-99,994 on plasma extravasation in dura mater and c-fos mRNA expression in trigeminal nucleus caudalis of rats , 1995, Neuropharmacology.

[3]  C. Swain,et al.  Piperidine-ether based hNK1 antagonists 2: Investigation of the effect of N-substitution , 1995 .

[4]  S. Harrison,et al.  Non-specific effects of the tachykinin NK1 receptor antagonist, CP-99,994, in antinociceptive tests in rat, mouse and gerbil. , 1994, European journal of pharmacology.

[5]  N. Rupniak,et al.  Differential inhibition of foot tapping and chromodacryorrhoea in gerbils by CNS penetrant and non-penetrant tachykinin NK1 receptor antagonists. , 1994, European journal of pharmacology.

[6]  C. Swain,et al.  Piperidine-ether based hNK1 antagonists 1: Determination of the relative and absolute stereochemical requirements , 1994 .

[7]  O. Berge,et al.  (±)-CP-96,345, an NK1 receptor antagonist, has local anaesthetic-like effects in a mammalian sciatic nerve preparation , 1994, Regulatory Peptides.

[8]  S. Ofner,et al.  CGP 49823, a novel NK1 receptor antagonist: Behavioural effects , 1994, Neuropeptides.

[9]  L. Bristow,et al.  Chromodacryorrhea and repetitive hind paw tapping: models of peripheral and central tachykinin NK1 receptor activation in gerbils. , 1994, European journal of pharmacology.

[10]  S. Iversen,et al.  Antinociceptive activity of NK1 receptor antagonists: non‐specific effects of racemic RP67580 , 1993, British journal of pharmacology.

[11]  R. Hargreaves,et al.  The tachykinin NK1 receptor antagonist CP-99,994 attenuates cisplatin induced emesis in the ferret. , 1993, European journal of pharmacology.

[12]  C. Bountra,et al.  Anti-emetic profile of a non-peptide neurokinin NK1 receptor antagonist, CP-99,994, in ferrets. , 1993, European journal of pharmacology.

[13]  A. Ganong,et al.  Pharmacology of CP-99,994; a nonpeptide antagonist of the tachykinin neurokinin-1 receptor. , 1993, The Journal of pharmacology and experimental therapeutics.

[14]  J. Kemp,et al.  Block of voltage‐dependent sodium currents by the substance P receptor antagonist (±)‐CP‐96,345 in neurones cultured from rat cortex , 1993, British journal of pharmacology.

[15]  A. Dickenson,et al.  The effect of intrathecal administration of RP67580, a potent neurokinin 1 antagonist on nociceptive transmission in the rat spinal cord , 1993, Neuroscience Letters.

[16]  R. Hargreaves,et al.  Effect of RP 67580, a non‐peptide neurokinin1 receptor antagonist, on facilitation of a nociceptive spinal flexion reflex in the rat , 1993, British journal of pharmacology.

[17]  M. P. Turpin,et al.  Characterisation of the tachykinin-induced hindlimb thumping response in gerbils , 1993, Neuropeptides.

[18]  T. Coderre,et al.  CP-96,345, but not its stereoisomer, CP-96,344, blocks the nociceptive responses to intrathecally administered substance P and to noxious thermal and chemical stimuli in the rat , 1993, Neuroscience.

[19]  A. Murase,et al.  Non‐specific activity of (±)‐CP‐96,345 in models of pain and inflammation , 1992, Regulatory peptides.

[20]  Anne W. Schmidt,et al.  The substance P receptor antagonist CP-96,345 interacts with Ca2+ channels. , 1992, European journal of pharmacology.

[21]  A. Malmberg,et al.  Hyperalgesia mediated by spinal glutamate or substance P receptor blocked by spinal cyclooxygenase inhibition. , 1992, Science.

[22]  Z. Wiesenfeld‐Hallin,et al.  Intrathecal CP-96,345 blocks reflex facilitation induced in rats by substance P and C-fiber-conditioning stimulation. , 1992, European journal of pharmacology.

[23]  S. Harrison,et al.  The non‐peptide NK1 receptor antagonist, (±)‐CP‐96,345, produces antinociceptive and anti‐oedema effects in the rat , 1992, British journal of pharmacology.

[24]  Y. de Koninck,et al.  Substance P-mediated slow excitatory postsynaptic potential elicited in dorsal horn neurons in vivo by noxious stimulation. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[25]  J. Henry,et al.  Novel substance P antagonist, CP-96,345, blocks responses of cat spinal dorsal horn neurons to noxious cutaneous stimulation and to substance P , 1991, Neuroscience Letters.

[26]  R. Hagan,et al.  Investigation into species variants in tachykinin NK1 receptors by use of the non‐peptide antagonist, CP‐96,345 , 1991, British journal of pharmacology.

[27]  R. Hagan,et al.  Receptor-selective, peptidase-resistant agonists at neurokinin NK-1 and NK-2 receptors: New tools for investigating neurokinin function , 1991, Neuropeptides.

[28]  T. Yamamoto,et al.  Stereospecific effects of a nonpeptidic NK1 selective antagonist, CP-96,345: antinociception in the absence of motor dysfunction. , 1991, Life sciences.

[29]  K. McCarson,et al.  Time course of the alteration in dorsal horn substance p levels following formalin: blockade by naloxone , 1990, Pain.

[30]  M. Zimmermann,et al.  Ethical guidelines for investigations of experimental pain in conscious animals , 1983, Pain.